From Obesity to Metabolic Health: Why Retatrutide Is a Game-Changer
Abstract Obesity and type 2 diabetes have become global health crises, fueling complications such as cardiovascular disease, fatty liver disease, and metabolic syndrome. While existing peptide-based therapies like semaglutide and tirzepatide have reshaped treatment, many patients still face incomplete results or intolerable side effects. Retatrutide, a next-generation triple-agonist peptide developed by Eli Lilly, offers a […]
LinkPeptide